biotech

BioPharma

9 Hot Takes from JPM24

I didn’t make it to this year’s J.P. Morgan Healthcare Conference in San Francisco, so I reached out to leaders from across the industry to hear how it went and learn about their takeaways from the event. This is a list of the nine most interesting responses that I received.

BioPharma

3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.